InvestSMART

Racura Oncology Ltd (ASX: RAC) - Announcements

Current share price for RAC : $2.090 0.095 (4.76%)+

ASX company news and announcements for Racura Oncology Ltd (RAC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Racura Oncology Ltd (RAC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Racura Oncology Ltd (RAC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Racura Oncology Ltd (RAC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$410 First Patient Safely Combine Dosed in Phase 1 RC220 Trial 19 Jun 2025 8:56AM $1.270 $2.090 risen by 64.57%
$410 Termination of City of Hope Global IP License 17 Jun 2025 8:57AM $1.130 $2.090 risen by 84.96%
$410 Application for quotation of securities - RAC 6 Jun 2025 11:54AM $1.180 $2.090 risen by 77.12%
$410 Notification of cessation of securities - RAC 3 Jun 2025 10:27AM $1.205 $2.090 risen by 73.44%
$410 Race Gold Coast Brisbane Investor Events 2 Jun 2025 12:14PM $1.258 $2.090 risen by 66.20%
$410 Application for quotation of securities - RAC 29 May 2025 4:11PM $1.340 $2.090 risen by 55.97%
$410 Application for quotation of securities - RAC 22 May 2025 11:14AM $1.390 $2.090 risen by 50.36%
$410 Application for quotation of securities - RAC 7 May 2025 11:09AM $1.200 $2.090 risen by 74.17%
$410 Notification of cessation of securities - RAC 6 May 2025 3:51PM $1.160 $2.090 risen by 80.17%
$410 Race Announces Key Senior Clinical Team Appointments 5 May 2025 8:57AM $1.210 $2.090 risen by 72.73%
$410 First Patient Dosed Safely in RC220 Phase 1 Trial 1 May 2025 8:57AM $1.045 $2.090 risen by 100%
$410 March 2025 Quarterly Activity Report and Appendix 4C 23 Apr 2025 8:41AM $0.960 $2.090 risen by 117.71%
$410 Enrolment Opened at Second Site for RC220 Phase 1 Trial 22 Apr 2025 8:56AM $0.925 $2.090 risen by 125.95%
$410 RC220 Phase 1 Trial Opens for Patient Enrolment 3 Apr 2025 8:57AM $1.145 $2.090 risen by 82.53%
$410 Ethics approval for RC220 Trial at Gosford Wyong Hospitals 31 Mar 2025 5:41PM $1.065 $2.090 risen by 96.24%
$410 Race Initiates First AU Site for Phase 1 Solid Tumour Trial 27 Mar 2025 3:53PM $1.070 $2.090 risen by 95.33%
$410 Race Investor Presentation 17 Mar 2025 4:53PM $1.175 $2.090 risen by 77.87%
$410 Race Online Investor Briefing Invitation 14 Mar 2025 11:08AM $1.165 $2.090 risen by 79.40%
$410 Ethics approval received for RC220 Phase 1 Trial 14 Mar 2025 8:47AM $1.030 $2.090 risen by 102.91%
$410 S&P DJI Announces March 2025 Quarterly Rebalance 7 Mar 2025 5:01PM $1.055 $2.090 risen by 98.10%
$410 Race Signs Contract for Phase 1 Trial of RC220 5 Mar 2025 8:58AM $1.060 $2.090 risen by 97.17%
$410 Appendix 4D & Half-Year Financial Statements 25 Feb 2025 1:42PM $1.180 $2.090 risen by 77.12%
$410 Application for quotation of securities - RAC 4 Feb 2025 1:06PM $1.250 $2.090 risen by 67.20%
$410 Quarterly Activity Report and Appendix 4C 31 Jan 2025 8:57AM $1.240 $2.090 risen by 68.55%
$410 Application for quotation of securities - RAC 16 Jan 2025 3:57PM $1.320 $2.090 risen by 58.33%

151 - 175 of 988 results

Page 7 of 40

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.